Proton therapy

P-Cure Demonstrates the Proton Therapy Equipment Can Now Be Installed In Existing Radiation Therapy Rooms

Retrieved on: 
Friday, March 25, 2022
Proton, Radiation, CE, Research, Neoplasm, Cancer, Proton therapy, TEL, Physician, Asian Pacific Development Center, FDA, Patient, Medical imaging

TEL AVIV, Israel, March 25, 2022 /PRNewswire-PRWeb/ -- P-Cure Ltd., the provider of the most compact 360° gantry-less adaptive proton therapy system, announced today the opening of a clinical research and training site within its headquarters in Israel. The site is conveniently located in a 20-minute drive from either Tel Aviv or Jerusalem and hosts the world's most compact proton therapy system, which is installed within the footprint of a standard radiotherapy linac vault.

Key Points: 
  • This training will enable fast technology adaptation by new treatment providers not familiar with proton therapy.
  • "Instead of building a stand-alone facility, a cancer treatment center can expand its treatment options by installating a compact P-Cure Proton Therapy System in already existing linac vault."
  • Unlike x-ray treatment, with proton therapy there is small amount of entrance radiation, but virtually none travels beyond the tumor.
  • The compact P-Cure system installed inside existing radiation oncology departments removes the economic barrier to offering more patients the benefits of proton therapy," says Marash.

American Shared Hospital Services Announces Fourth Quarter and Year End 2021 Earnings Conference Call

Retrieved on: 
Friday, March 18, 2022
IMRT, GLOBE, NYSE, Company, AMS, Radiosurgery, Trigeminal neuralgia, Pain scale, Malignancy, Pectus carinatum, IGRT, CA, Proton therapy, Medical imaging

San Francisco, CA, March 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its fourth quarter and year end 2021 financial results on Thursday, March 24, 2022 at 4:00pm ET / 1:00pm PT. The fourth quarter and year end 2021 financial results press release will be issued premarket the morning of Thursday, March 24, 2022.

Key Points: 
  • San Francisco, CA, March 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its fourth quarter and year end 2021 financial results on Thursday, March 24, 2022 at 4:00pm ET / 1:00pm PT.
  • The fourth quarter and year end 2021 financial results press release will be issued premarket the morning of Thursday, March 24, 2022.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.

RaySearch Laboratories : Year-end report 2021

Retrieved on: 
Wednesday, February 23, 2022
Proton, POS, Webcast, Genolier Swiss Medical Network SA, SEK, Brachytherapy, CFO, Operating cost, Proton therapy, Uncertainty, COVID-19, Karolinska Institute, OIS, TCS, OAS, RaySearch Laboratories, EU, IBA, TPS, FLASH, Nasdaq Stockholm, CEO, CET, Weapon, Pharmaceutical industry, Medical imaging, Flour

RaySearch secured a large order for RayStation from Lanzhou Ion Therapy, a Chinese manufacturer of accelerator systems.

Key Points: 
  • RaySearch secured a large order for RayStation from Lanzhou Ion Therapy, a Chinese manufacturer of accelerator systems.
  • RaySearch and Mevion Medical Systems have expanded their collaboration on the development of advanced treatment planning techniques for FLASH delivery with the Mevion S250i Proton Therapy System.
  • New CFO of RaySearch took over on November 15, 2021.
  • RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment.

Mevion Selected to Equip Proton Therapy Center at Tongji Hospital in China

Retrieved on: 
Monday, February 21, 2022
Oncology, Education, Health, Medical Devices, Hospitals, University, Biotechnology, Proton, Risk, Huachung University, Tongji Hospital station, Growth, Scan (company), Education, Adaptation, Varian Medical Systems, Proton therapy, Neoplasm, Huazhong University of Science and Technology, Tongji, Multimedia, Science, Tongji Medical College, Patient, U.S. News & World Report Best Hospitals Rankings, PBS, Faculty, LinkedIn, Research, Medical imaging, Medicine, Central China, Technology, Mevion Medical Systems, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, MEVION MEDICAL SYSTEMS, TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

Mevion Medical Systems today announced it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System in Wuhan, China.

Key Points: 
  • Mevion Medical Systems today announced it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System in Wuhan, China.
  • Founded in 1900 and listed as the 6th top hospital in Fudans 2020 China Hospital Ranking , Tongji Hospital provides over 6 million annual outpatient visits.
  • The contract for the new proton therapy center was completed in late 2021, and construction of the new 135,000 square-foot proton therapy center at Tongji Hospitals Optics Valley campus is expected to be completed by December 2022.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

American Shared Hospital Services Announces Preliminary Results for Fourth Quarter and Full Year 2021

Retrieved on: 
Tuesday, February 15, 2022
Proton therapy, Income, NYSE, Trigeminal neuralgia, IGRT, Annual general meeting, CMS, Risk, Company, SEC, U.S. Securities and Exchange Commission, SAN, Radiosurgery, Leeds Gamma Knife Centre, CA, HVS Global Hospitality Services, Security (finance), Annual report, Malignancy, GLOBE, AMS, Pectus carinatum, Growth, COVID-19, IMRT, Century, Video game

SAN FRANCISCO, CA, Feb. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced selected preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2021.

Key Points: 
  • SAN FRANCISCO, CA, Feb. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced selected preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2021.
  • Fourth quarter 2021 revenue of $4.7 million in combination with lower costs of revenue, resulted in higher preliminary gross margin and operating income than the previous three quarters of 2021.
  • Revenue in the fourth quarter grew modestly quarter-over-quarter and rebounded from the lower levels of the previous quarter.
  • American Shared Hospital Services' final fourth quarter and full year 2021 results will be filed with the SEC upon completion of the annual year end audit, which is expected in late March 2022.

Mevion Selected to Equip New Proton Therapy and Research Center in San Antonio

Retrieved on: 
Wednesday, February 9, 2022
Biotechnology, Oncology, Health, Medical Devices, Hospitals, University, Education, Other Health, Proton, University, PBS, University of Texas Health Science Center at San Antonio, LinkedIn, School, Spine, Nursing, Dentistry, Beaumont Hospital, Royal Oak, Proton therapy, Multimedia, University of Alabama, Varian Medical Systems, NCI, Medicine, Science, Time, YouTube, Research, COVID-19, Twitter, Cancer, PI, Heart, Risk, Secondary malignant neoplasm, Technology, Patient, Hospital, MD, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Education, Brain, CEO, Health, University of Texas System, Instagram, Partnership, UT Health San Antonio Cancer Center, Education, Medical imaging, Facebook

Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center.

Key Points: 
  • Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center.
  • It will be the first proton therapy system in San Antonio and South Texas to provide this advanced alternative to conventional radiation therapy for cancer.
  • The MEVION S250i with HYPERSCAN has advanced the benefits of proton therapy by enabling faster and sharper delivery of therapeutic radiation.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi's First Dedicated Compact Proton Therapy System

Retrieved on: 
Wednesday, February 2, 2022
Proton, Security, Proton therapy, TSE, Patient, Neoplasm, Cone, Harman Becker Automotive Systems, Ion, Hokkaido University, Japan Society for the Promotion of Science, Carbon, Cancer, Hospital, Environment, Particle therapy, Cone beam computed tomography, FIRST, Time, Movement, Quality of life, Respiration, Light, Nursing, Medical imaging, Pharmaceutical industry, Technology, Industry, Science

TOKYO, Feb 2, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) has announced that "Shonan Kamakura Advanced Medical Center" at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, "the system") has been installed, has commenced treatment with the system on 31 January 2022.

Key Points: 
  • TOKYO, Feb 2, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501) has announced that "Shonan Kamakura Advanced Medical Center" at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, "the system") has been installed, has commenced treatment with the system on 31 January 2022.
  • Shonan Kamakura Advanced Medical Center is a medical facility providing comprehensive cancer treatment, including advanced radiotherapy, built adjacent to the site of Shonan Kamakura General Hospital by Tokushukai Group Medical Corporation, which operates approximately 400 medical facilities and nursing homes throughout Japan.
  • Until now, there have been no proton therapy facilities in Kanagawa Prefecture, where the center is located, but the compact proton therapy system, with its reduced footprint, makes it possible to install a proton therapy facility on a limited site close to the city center.
  • In response to the growing worldwide demand for smaller proton therapy systems, Hitachi has developed the proton therapy system, which is specifically designed for a single treatment room.

NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets

Retrieved on: 
Tuesday, February 1, 2022
ACT, Rutgers Cancer Institute of New Jersey, Private Securities Litigation Reform Act, Forward-looking statement, RWJBarnabas Health, Patient, Proton therapy, CAR, Rutgers University, Nanoparticle, Haematopoietic system, Robert Wood Johnson University Hospital, NEXI, Infection, Neoplasm, Toxic epidermal necrolysis, Cancer, National Cancer Institute, SEC, R, AIM, Immunotherapy, Technology, Outline of health sciences, Teaching hospital, U.S. Securities and Exchange Commission, Rutgers Biomedical and Health Sciences, Annual report, Precision medicine, NCI-designated Cancer Center, Company, GLOBE, Degenerative disease, State university system, Senior, Cancer Institute, Survival, Security (finance), Therapy, Terminology, AML, Wilms' tumor, Multiple myeloma, Nasdaq, Vaccine, Pharmaceutical industry

The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers.

Key Points: 
  • The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers.
  • Neuroendocrine tumors are being diagnosed with increasing frequency in the United States and represent a large unmet medical need, said Dr. Jerry Zeldis, NexImmunes Executive Vice President, R&D.
  • With Dr. Libutti, we hope to discover and develop novel treatments utilizing our AIM ACT platform that may improve the timely and effective treatment of neuroendocrine neoplasia.
  • The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response.

Probo Medical Acquires REMETRONIX

Retrieved on: 
Thursday, January 20, 2022
Radiology, Health, Practice Management, Medical Devices, Proton, Google Images, Standards organization, Proton therapy, COO, ISO, PET-CT, Partnership, CEO, Solution, Transport, MRI, Statistics, Medicine, Certification, ISO 9001:2015, Maintenance, United Kingdom, Acquisition, Medical imaging, Fluoroscopy, Mammography, Probo Medical, REMETRONIX, PROBO MEDICAL, REMETRONIX

Probo Medical (Probo), a leading global provider of medical imaging equipment, parts, repair and service, today announced the completion of its acquisition of REMETRONIX.

Key Points: 
  • Probo Medical (Probo), a leading global provider of medical imaging equipment, parts, repair and service, today announced the completion of its acquisition of REMETRONIX.
  • Based in Port St. Lucie, Florida, REMETRONIX provides transportation, rigging, installation, de-installation, maintenance, storage and refurbishment of medical imaging equipment.
  • We are fortunate to partner with the REMETRONIX team whose expertise in this space is unmatched, said Michael Asmer, CEO of Probo Medical.
  • Our partnership with Probo Medical will provide REMETRONIX with the resources necessary to develop increasingly elevated solutions for our customers, said REMETRONIX President & CEO Russell Knowles.

PROCURE MARKS 6,000TH PATIENT TO COMPLETE TREATMENT

Retrieved on: 
Tuesday, January 18, 2022
Proton, Lung, Patient, Prostate, Proton therapy, Prostate cancer, Freedom, Physician, CentraState Medical Center, Procurement, Radiation, Cancer, Sarcoma, Northwell Health, Memorial Sloan Kettering Cancer Center, Extrapyramidal system, Head, Neck, New York University Grossman School of Medicine, Breast, Brain, Medical imaging, Montefiore

SOMERSET, N.J., Jan. 18, 2022 /PRNewswire/ -- ProCure Proton Therapy Center surpassed a major milestone Monday when Edmund Laska, 71, of Staten Island, NY, became its 6,000th patient to complete treatment since the center opened 10 years ago.

Key Points: 
  • SOMERSET, N.J., Jan. 18, 2022 /PRNewswire/ -- ProCure Proton Therapy Center surpassed a major milestone Monday when Edmund Laska, 71, of Staten Island, NY, became its 6,000th patient to complete treatment since the center opened 10 years ago.
  • "We were truly honored to play a part in Mr. Laska's cancer journey," said Dr. Brian Chon, ProCure Medical Director.
  • Treating 6,000 patients is a testament to the great team we have at ProCure and the effectiveness of proton therapy."
  • ProCure, located in Somerset, NJ, became the tri-state region's first proton therapy facility in 2012.